• Something wrong with this record ?

Efficacy and safety of Dr Michaels® (Soratinex®) product family for the topical treatment of psoriasis: a monitored status study

K. França, F. Novotny, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, M. Tirant, MG. Roccia, T. Lotti,

. 2016 ; 30 (2 Suppl 3) : 115-9.

Language English Country Italy

Document type Clinical Trial, Journal Article

Persistent link   https://www.medvik.cz/link/bmc19001362

The aim of the study was to investigate the efficacy and safety of Michaels® (Soratinex®) remedies in patients suffering from chronic plaque psoriasis in a Czech population. Seventy-five (34 female/41 male) patients, aged 18-72 years old (mean age: 38.5 years) with mild to severe plaque psoriasis participated in the study. The products, including cleansing gel, ointment and skin conditioner, containing fruit acid complex, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Histologic variables and various blood picture parameters, including FW, glucose, cholesterol, triacylglyceroles, bilirubin, GMT, ALT, AST, creatinine, uric acid and urea in blood were monitored, before and after therapy with Michaels® (Soratinex®) treatment. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done at time 0, and after 2, 4, 6 and 8 weeks. Patient´s improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks using Dr Michaels® (Soratinex®) treatment course, 5 patients had a moderate improvement, with the resolution of 25-50% of skin lesions; 11 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 50 patients had an outstanding improvement, with the regression of 76-100% of lesions. Only 4 patients did not achieve an improvement of psoriasis. Six patients experienced folliculitis, which resolved without cessation of treatment. Three patients worsened and discontinued treatment. Six patients dropped out because of non-compliance. The blood results and histologic findings were all normal. Our investigation shows that Dr Michaels® (Soratinex®) products can be safely and successfully used in the treatment of chronic plaque psoriasis.

000      
00000naa a2200000 a 4500
001      
bmc19001362
003      
CZ-PrNML
005      
20190311103859.0
007      
ta
008      
190107s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)27498668
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a França, K $u Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.
245    10
$a Efficacy and safety of Dr Michaels® (Soratinex®) product family for the topical treatment of psoriasis: a monitored status study / $c K. França, F. Novotny, J. Hercogová, M. Fioranelli, S. Gianfaldoni, AA. Chokoeva, G. Tchernev, U. Wollina, M. Tirant, MG. Roccia, T. Lotti,
520    9_
$a The aim of the study was to investigate the efficacy and safety of Michaels® (Soratinex®) remedies in patients suffering from chronic plaque psoriasis in a Czech population. Seventy-five (34 female/41 male) patients, aged 18-72 years old (mean age: 38.5 years) with mild to severe plaque psoriasis participated in the study. The products, including cleansing gel, ointment and skin conditioner, containing fruit acid complex, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Histologic variables and various blood picture parameters, including FW, glucose, cholesterol, triacylglyceroles, bilirubin, GMT, ALT, AST, creatinine, uric acid and urea in blood were monitored, before and after therapy with Michaels® (Soratinex®) treatment. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done at time 0, and after 2, 4, 6 and 8 weeks. Patient´s improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks using Dr Michaels® (Soratinex®) treatment course, 5 patients had a moderate improvement, with the resolution of 25-50% of skin lesions; 11 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 50 patients had an outstanding improvement, with the regression of 76-100% of lesions. Only 4 patients did not achieve an improvement of psoriasis. Six patients experienced folliculitis, which resolved without cessation of treatment. Three patients worsened and discontinued treatment. Six patients dropped out because of non-compliance. The blood results and histologic findings were all normal. Our investigation shows that Dr Michaels® (Soratinex®) products can be safely and successfully used in the treatment of chronic plaque psoriasis.
650    _2
$a aplikace lokální $7 D000287
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a Česká republika $7 D018153
650    _2
$a emulgátory $x aplikace a dávkování $x terapeutické užití $7 D045703
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a masti $x aplikace a dávkování $x terapeutické užití $7 D009824
650    12
$a fytoterapie $7 D008517
650    _2
$a psoriáza $x farmakoterapie $7 D011565
650    _2
$a péče o kůži $x metody $7 D017592
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Novotny, F $u PROSANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.
700    1_
$a Hercogová, J $u 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Fioranelli, M $u Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy.
700    1_
$a Gianfaldoni, S $u Dermatological Department University of Pisa, Pisa, Italy.
700    1_
$a Chokoeva, A A $u Onkoderma - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.
700    1_
$a Tchernev, G $u Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
700    1_
$a Wollina, U $u Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
700    1_
$a Tirant, M $u Psoriasis and Skin Clinic, Melbourne, Australia.
700    1_
$a Roccia, M G $u University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
700    1_
$a Lotti, T $u Chair of Dermatology, University of Rome "G. Marconi" Rome, Italy.
773    0_
$w MED00008336 $t Journal of biological regulators and homeostatic agents $x 0393-974X $g Roč. 30, č. 2 Suppl 3 (2016), s. 115-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27498668 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190311104218 $b ABA008
999    __
$a ok $b bmc $g 1364059 $s 1039485
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 30 $c 2 Suppl 3 $d 115-9 $i 0393-974X $m Journal of Biological Regulators & Homeostatic Agents $n J Biol Regul Homeost Agents $x MED00008336
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options